Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Novo Nordisk is doing exceptionally well in the ... which is a long-acting growth hormone. Thanks to less frequent injections and the fact that it is not inferior to Norditropin, Sogroya is ...

A next-generation Novo Nordisk metabolic disorder drug led to ... Cagrilintide, a long-acting version of the hormone amylin, activates the amylin receptor, which plays a role in regulating blood ...

Novo Nordisk has ... version of parathyroid hormone (PTH), which is for the treatment of hypoparathyroidism in adults, and Skytrofa (lonapegsomatropin), a long-acting growth hormone for children ...

Novo Nordisk A/S ... rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart ...